Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.06 USD
Change Today -0.0069 / -11.13%
Volume 67.6K
IMUN On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Berlin
As of 3:51 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

immune therapeutics inc (IMUN) Snapshot

Open
$0.06
Previous Close
$0.06
Day High
$0.06
Day Low
$0.06
52 Week High
05/6/14 - $0.89
52 Week Low
04/14/15 - $0.05
Market Cap
8.0M
Average Volume 10 Days
141.2K
EPS TTM
--
Shares Outstanding
144.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNE THERAPEUTICS INC (IMUN)

Related News

No related news articles were found.

immune therapeutics inc (IMUN) Related Businessweek News

No Related Businessweek News Found

immune therapeutics inc (IMUN) Details

Immune Therapeutics, Inc. focuses on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases, and immune disorders in the United States. The company develops IRT-101, an active immunotherapy systemic administration of methionine-enkephalin that works by stimulating and/or regulating a patient’s immune system against infectious diseases, autoimmune diseases, immune disorders, and tumor cells. It also develops IRT-103, an adaptive immunotherapy for the treatment of various autoimmune diseases, such as Crohn's disease and multiple sclerosis; HIV/AIDS; and cancer. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.

6 Employees
Last Reported Date: 03/31/15

immune therapeutics inc (IMUN) Top Compensated Officers

Chairman, Chief Executive Officer and Founder
Total Annual Compensation: $341.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $60.0K
Chief Science Officer
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

immune therapeutics inc (IMUN) Key Developments

Immune Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Immune Therapeutics, Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Turner, Stone & Company, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc

Immune Therapeutics, Inc. announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.

Immune Therapeutics, Inc. Announces Board Changes

Immune Therapeutics, Inc. announced that Vincent Butta, a new director appointed to fill a vacancy, and Edward Teraskiewicz, a director elected at the 2014 annual meeting of shareholders, joined the board on January 13, 2015. Vincent Butta was appointed by the board of directors on January 13, 2015 to fill a vacancy on the board. Mr. Butta is a visionary executive business leader with a 30-year track record in Operations, Executive Management, Technology, Supply Chain Management, Marketing, Sales Management, Brand Creation, Licensing, Digital and Social Media, and Strategic Planning. Two of the board members elected at the 2014 annual meeting of shareholders, Roger Bozarth and Joel Yanowitz, will not join the board in January as agreed as Immune Therapeutics has not yet purchased D&O insurance; however, the company expects that Mr. Bozarth will work with the company in an advisory capacity. Jay Goldstein, a director that was also elected at the 2014 annual meeting, was unable to accept his election to the board as a new position taken by Mr. Goldstein limits his ability to take outside board seats.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUN:US $0.06 USD -0.0069

IMUN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUN.
View Industry Companies
 

Industry Analysis

IMUN

Industry Average

Valuation IMUN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE THERAPEUTICS INC, please visit www.tnibiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.